All In Biotech

Drug Trial Radar · NCT02220920

Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin (TA-7284) as add-on to Insulin in Subjects With Type 2 Diabetes Mellitus

Last checked: Nov 20, 2026Latest source record: Jan 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 146 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

146

Actual

Start

Aug 2014

Primary completion

Jul 2015

Study completion Jul 2015

Sponsor

Lead sponsor
Tanabe Pharma CorporationIndustry
Sponsor type
Industry
First posted
Aug 20, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of Canagliflozin (TA-7284) in combination with Insulin in patients with type 2 Diabetes for 16 weeks administration.

Conditions

  • Type 2 Diabetes Mellitus

Interventions

  • Canagliflozin (TA-7284)Drug

    The patients will receive Canagliflozin orally for 16 weeks

  • PlaceboDrug

    The patients will receive Placebo orally for 16 weeks

  • InsulinDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in HbA1c From BaselineTime frame: baseline and Week 16

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Reserch site

    Chūbu, Japan

  • Reserch site

    Chugoku, Japan

  • Reserch site

    Hokkaido, Japan

  • Reserch site

    Kanto, Japan

  • Reserch site

    Kinki, Japan

  • Reserch site

    Kyushu, Japan

  • Reserch site

    Tōhoku, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.